224 related articles for article (PubMed ID: 36750524)
1. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
[TBL] [Abstract][Full Text] [Related]
2. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
3. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.
Hoshino T; Naganuma A; Furusawa A; Suzuki Y; Hirai K; Sakamoto I; Ogawa T; Ogawa A; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Aug; 15(4):776-783. PubMed ID: 35585285
[TBL] [Abstract][Full Text] [Related]
4. Two elder cases of hepatocellular carcinoma adjacent to intrahepatic vessels successfully treated by carbon ion radiotherapy.
Takakusagi S; Takagi H; Shibuya K; Kosone T; Sato K; Kakizaki S; Ohno T; Uraoka T
Clin J Gastroenterol; 2020 Oct; 13(5):920-926. PubMed ID: 32529487
[TBL] [Abstract][Full Text] [Related]
5. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
6. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
7. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
8. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi N
Liver Cancer; 2023 Sep; 12(4):321-338. PubMed ID: 37901197
[TBL] [Abstract][Full Text] [Related]
9. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
[TBL] [Abstract][Full Text] [Related]
10. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
[TBL] [Abstract][Full Text] [Related]
11. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
15. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma.
Mitsuyama Y; Kageyama K; Shinkawa H; Yamamoto A; Jogo A; Sohgawa E; Tanaka S; Takemura S; Kubo S; Ishizawa T; Miki Y
Radiol Case Rep; 2023 Sep; 18(9):3037-3040. PubMed ID: 37434611
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.
Kurisaki K; Soyama A; Hara T; Matsushima H; Imamura H; Tanaka T; Adachi T; Ito S; Kanetaka K; Hidaka M; Okano S; Eguchi S
Dig Surg; 2023; 40(1-2):84-89. PubMed ID: 36848877
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab.
Shigefuku R; Yoshikawa K; Tsukimoto M; Owa H; Tamai Y; Tameda M; Ogura S; Sugimoto R; Tanaka H; Eguchi A; Sugimoto K; Hasegawa H; Iwasa M; Nakagawa H
Intern Med; 2023 Feb; 62(4):539-543. PubMed ID: 35732454
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
[TBL] [Abstract][Full Text] [Related]
20. Durable Stable Disease by Atezolizumab/Bevacizumab Can Provide Long-term Survival of Patients With Hepatocellular Carcinoma Lung Metastases.
Motohara T; Yamamura K; Miyamoto H; Ueno S; Takeno H; Nagayama Y; Oda E; Karashima R; Ozaki N; Miyata T; Mima K; Okabe H; Isiko T; Beppu T
In Vivo; 2023; 37(5):2268-2275. PubMed ID: 37652506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
